Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Small

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bevacizumab and everolimus in renal cancer: a rational way forwardWalter M Stadler, George Phillips, Daniel J George, et al.
Urologic Oncology|October 7, 2004
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901Asim Amin, Susan Halabi, Edward P Gelmann, et al.
Cancer|November 8, 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811William Kevin Kelly, Susan Halabi, Aymen Elfiky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapyRobert W Ross, Judith Manola, Kristen Hennessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901Walter M Stadler, Gary Rosner, Eric Small, et al.
Cancer|October 7, 2004
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapyMatthew R Smith, Judith Manola, Donald S Kaufman, et al.
JCO Oncology Practice|February 23, 2022
Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical TrialHala T Borno, Li Zhang, Sylvia Zhang, et al.
BJU International|April 25, 2017
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancerJ Kellogg Parsons, John P Pierce, James Mohler, et al.
Pilot and Feasibility Studies|November 14, 2019
A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching toolHala T Borno, Brian M Bakke, Celia Kaplan, et al.
EMBO Molecular Medicine|December 28, 2020
MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodelingJiangbin Wu, Kadiam C Venkata Subbaiah, Feng Jiang, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bevacizumab and everolimus in renal cancer: a rational way forwardWalter M Stadler, George Phillips, Daniel J George, et al.
Urologic Oncology|October 7, 2004
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901Asim Amin, Susan Halabi, Edward P Gelmann, et al.
Cancer|November 8, 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811William Kevin Kelly, Susan Halabi, Aymen Elfiky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapyRobert W Ross, Judith Manola, Kristen Hennessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901Walter M Stadler, Gary Rosner, Eric Small, et al.
Cancer|October 7, 2004
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapyMatthew R Smith, Judith Manola, Donald S Kaufman, et al.
JCO Oncology Practice|February 23, 2022
Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical TrialHala T Borno, Li Zhang, Sylvia Zhang, et al.
BJU International|April 25, 2017
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancerJ Kellogg Parsons, John P Pierce, James Mohler, et al.
Pilot and Feasibility Studies|November 14, 2019
A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching toolHala T Borno, Brian M Bakke, Celia Kaplan, et al.
EMBO Molecular Medicine|December 28, 2020
MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodelingJiangbin Wu, Kadiam C Venkata Subbaiah, Feng Jiang, et al.
Pageof 4